Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, ABI to Mail Merger Prospectus to Shareholders This Week

NEW YORK (GenomeWeb News) – Invitrogen and Applied Biosystems said today that the registration statement for their proposed $6.7 billion merger has become effective, and the firms will mail a joint proxy statement/prospectus to their respective shareholders this week.
 
Each firm will hold a special meeting of shareholders on Oct. 16 to vote on the proposed deal. ABI and Invitorgen shareholders of record as of the close of business on Sept. 5 are entitled to vote at the meetings.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.